Immunogen Inc was incorporated in 1981, in Massachusetts. The Company is a biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products. The Company develops its own product candidates using its ADC technology. It has three wholly owned, clinical-stage anticancer compounds: mirvetuximab soravtansine, or IMGN853, coltuximab ravtansine, formerly SAR3419, and IMGN529 and have reported preclinical data for IMGN779, which expected to be next clinical-stage compound. IMGN779 is the first ADC utilizing GN technology. The compound with ADC technology is Roche's marketed product, Kadcyla (ado-trastuzumab emtansine). Eight other ADC compounds and one non-ADC, or 'naked' antibody product candidate, are in clinical testing. The Company's current partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company, or Lilly, Novartis Institutes for BioMedical Research, Inc., or Novartis, the Roche Group, Sanofi and Takeda. Its competitors include pharmaceutical companies and other biotechnology firms, Pfizer, Seattle Genetics, Roche and Bristol-Myers Squibb. Its patent portfolio had approximately 659 issued patents and approximately 645 pending patent applications all over the world. The Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.